UroGen Pharma Ltd [URGN] stock is trading at $16.89, up 3.05%. An important factor to consider is whether the stock is rising or falling in short-term value. The URGN shares have gain 12.52% over the last week, with a monthly amount glided 32.26%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on February 08, 2023, when Jefferies downgraded its rating to a Hold and also revised its price target to $10 from $35. Previously, Berenberg started tracking the stock with Buy rating on April 27, 2022, and set its price target to $20. On April 16, 2020, H.C. Wainwright reiterated its Buy rating and revised its price target to $57 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $53 on April 13, 2020. National Securities initiated its recommendation with a Neutral and recommended $37 as its price target on January 09, 2020. In a note dated May 29, 2019, Goldman initiated an Neutral rating.
UroGen Pharma Ltd [URGN] stock has fluctuated between $8.69 and $24.13 over the past year. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $16.89 at the most recent close of the market. An investor can expect a potential return of 148.67% based on the average URGN price forecast.
Analyzing the URGN fundamentals
UroGen Pharma Ltd [NASDAQ:URGN] reported sales of 84.30M for the trailing twelve months, which represents a growth of 9.24%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -1.19%, and Net Profit Margin reading is -1.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is 1.46 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.46 points at the first support level, and at 16.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.31, and for the 2nd resistance point, it is at 17.73.
Ratios To Look Out For
For context, UroGen Pharma Ltd’s Current Ratio is 7.47. On the other hand, the Quick Ratio is 7.20, and the Cash Ratio is 5.02. Considering the valuation of this stock, the price to sales ratio is 8.25.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jun 10 ’24 when 5153.0 shares were sold. Chief Medical Officer, Schoenberg Mark completed a deal on Mar 18 ’24 to sell 12000.0 shares. Meanwhile, General Counsel Smith Jason Drew sold 4993.0 shares on Jan 31 ’24.
